" class="no-js "lang="en-US"> Jim Lang - Medtech Alert
Thursday, March 30, 2023

Breaking News

Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells Hansa Biopharma Announces Positive Reimbursement in Spain for Idefirix as Desensitization Treatment for Patients in Kidney Transplantation Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices
Jim Lang

Jim Lang

About Jim Lang

As Chief Executive Officer, Jim leads EVERSANA’s vision to accelerate the industry’s shift to patient-centered, value-based care – creating a healthier world for all. Lang brings more than 30 years of senior leadership experience in leading, advising and funding mission-driven health care companies. Lang previously served as CEO for several large organizations, and also spent nearly two decades building a premier strategy consultant firm. Lang holds a Master of Business Administration from Dartmouth University, and is an executive advisor with Water Street Healthcare Partners.

Related Story

Diseases

 Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S. | Pharmtech Focus|Nemaura and EverEVERSANA Sign Preliminary Agreement for Large-scale Launch of Nemaura’s Diabetes Management Program in the U.S. | Pharmtech Focus

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

September 28 2022

Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and […]

News

 EVERSANA Unveils Global Price and Market Access Solution NAVLIN by EVERSANA | Pharmtech Focus

EVERSANA Unveils Global Price and Market Access Solution NAVLIN by EVERSANA

March 18 2022

EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today […]

Industry News

 EVERSANA Acquires Protean; Strengthens Operational Strategy and Excellence in Market Access

EVERSANA Acquires Protean; Strengthens Operational Strategy and Excellence in Market Access, Channel and Patient Services

October 18 2021

EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, today announced […]

News

 EVERSANA ™ Expands Medical Information and Integrated Compliance Services Across Europe | Pharmtech Focus

EVERSANA ™ Expands Medical Information and Integrated Compliance Services Across Europe

June 21 2021

EVERSANA ™, the pioneer of next generation commercial services to the global life sciences industry, today […]

Cardiovascular

 GENinCode Announces Major US Commercialisation Partnership with EVERSANA | Pharmtech Focus

GENinCode Announces Major US Commercialisation Partnership with EVERSANA

June 14 2021

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of […]